Harmony Biosciences Holdings, Inc. (HRMY)

Market Cap	1.79B +5.8%
Revenue (ttm)	899.11M +20.7%
Net Income	145.62M -4.7%
EPS	2.48 -5.4%
Shares Out	57.89M
PE Ratio	12.45
Forward PE	8.37
Dividend	n/a
Ex-Dividend Date	n/a

Volume	329,870
Open	30.96
Previous Close	30.83
Day's Range	30.65 - 31.40
52-Week Range	25.52 - 40.87
Beta	0.97
Analysts	Buy
Price Target	42.33 (+37.12%)
Earnings Date	May 7, 2026

About HRMY

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in P...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 19, 2020
• Employees: 293
• Stock Exchange: NASDAQ
• Ticker Symbol: HRMY
• Website: https://www.harmonybiosciences.com

Financial Performance

In 2025, HRMY's revenue was $868.45 million, an increase of 21.51% compared to the previous year's $714.73 million. Earnings were $158.69 million, an increase of 9.07%.

Analyst Summary

According to 9 analysts, the average rating for HRMY stock is "Buy." The 12-month stock price target is $42.33, which is an increase of 37.12% from the latest price.

Price Target

$42.33

(37.12% upside)

Analyst Consensus: Buy